CompAI Healthcare (Suzhou) Co., ltd

CompAI Healthcare (Suzhou) Co., Ltd. specializes in tissue specimen x-ray systems for in vitro diagnostic (IVD) use. These devices are designed to produce high-resolution images of small biological samples, such as tissue specimens, enabling detailed examination in laboratory settings. The company’s portfolio includes systems like the TrueView Core 100Pro-US and TrueView 200 Pro-US, which are tailored for specimen radiography.

CompAI Healthcare (Suzhou) Co., Ltd. is headquartered in China, which influences its regulatory strategy for device authorization. While the company’s devices are subject to global regulatory scrutiny—such as FDA requirements in the U.S.—its location may impact compliance pathways, supply chain logistics, and local market access. However, individual devices must still meet the specific regulatory standards of each jurisdiction where they are marketed.

CompAI Healthcare’s devices are classified as Class II under regulatory frameworks like the FDA. This classification indicates a moderate level of risk, requiring pre-market clearance (e.g., via a 510(k) submission) to demonstrate safety and effectiveness compared to a predicate device. Class II classification typically involves stricter manufacturing controls and post-market surveillance than lower-risk devices but is less stringent than Class III (high-risk) devices.

CompAI Healthcare’s devices are listed in the FDA’s 510(k) and Unique Device Identifier (UDI) registries. The 510(k) listing signifies that the devices have undergone pre-market review to confirm they are substantially equivalent to a legally marketed predicate device, meeting FDA safety and performance requirements. The UDI listing ensures traceability and transparency in the supply chain, allowing regulators, healthcare providers, and patients to identify and track specific devices throughout their lifecycle.

CompAI Healthcare’s tissue specimen x-ray systems are designed for IVD use because they are intended to diagnostically examine biological samples outside of a living organism—such as tissue biopsies—in a controlled laboratory environment. These systems provide high-resolution imaging critical for identifying cellular structures, detecting abnormalities, or guiding further diagnostic procedures. The classification as IVD devices ensures they meet rigorous standards for accuracy, reliability, and clinical utility in diagnostic workflows.